VivoSeq
Other

Palmoplantar Pustulosis

15

Pipeline Programs↗

3

Active Trials↗

14

Companies Involved↗

Palmoplantar Pustulosis is an emerging landscape with 15 programs across 14 companies. The most active players are Boehringer Ingelheim, Aristea Therapeutics, Inc., Vanda Pharmaceuticals. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

15/100

Mech. Concentration

10/100

Completion Rate

75/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2A

Aristea Therapeutics, Inc.

1 program

Phase 2V

Vanda Pharmaceuticals

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

15programs
Small molecule747%
Monoclonal antibody640%
Protein / enzyme213%

Modality classified for 94% of 16 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed12 · 63%
Terminated4 · 21%
Recruiting3 · 16%

Clinical Trials

Trial Activity

19 trials

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
Recruiting·XXijing Hospital·N/A·NCT07270003·60 enrolled
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Recruiting·LEO Pharma logoLEO Pharma·Phase 2·NCT07013201·135 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Recruiting·UCB logoUCB·Phase 3·NCT07219420·320 enrolled
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT04015518·152 enrolled
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 3·NCT04061252·126 enrolled
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Completed·Amgen logoAmgen·Phase 2·NCT04057937·90 enrolled
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Completed·AbbVie logoAbbVie·Phase 3·NCT04451720·119 enrolled
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
Completed·Amgen logoAmgen·Phase 3·NCT05174065·176 enrolled
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Completed·VVanda Pharmaceuticals·Phase 2·NCT03633396·59 enrolled
Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Completed·—·Phase 2·NCT04572997·21 enrolled
A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT01845987·49 enrolled
A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Completed·IInnovaderm Research Inc.·Phase 3·NCT00353119·15 enrolled
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
Completed·AAristea Therapeutics, Inc.·Phase 2·NCT03988335·35 enrolled
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT03135548·59 enrolled
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT02641730·159 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)